GOOD LABORATORY PRACTICE (GLP)

GLP is a formal regulatory framework designed to ensure the quality, integrity, and traceability of non-clinical laboratory studies that are submitted to regulatory authorities for safety assessment. It is not concerned with product manufacturing or clinical use, but rather with the scientific validity of data generated during preclinical testing. These studies typically involve chemical substances, pharmaceuticals, pesticides, veterinary medicines, industrial chemicals, and environmental agents before they are tested in humans or released into ecosystems. The central function of GLP is to guarantee that the data generated in such studies is reliable enough to support regulatory decision-making. At its core, GLP is fundamentally a data integrity system. It does not judge whether a substance is safe or toxic; instead, it ensures that whatever conclusions are drawn about safety are based on transparent, reproducible, and auditable experimental evidence. Regulatory agencies such as the Organisation for Economic Co-operation and Development(OECD), United States Food and drug Administration (US FDA), and European Medicines Agency rely heavily on GLP compliance because it provides confidence that data from different laboratories, countries, and organizations can be compared and trusted. Without GLP, there would be no standardized mechanism to verify whether preclinical safety data was generated under controlled and unbiased conditions.

GLP applies strictly to non-clinical studies, meaning experiments conducted outside human subjects. These include toxicology testing in animals, carcinogenicity studies, genotoxicity assays, reproductive toxicity studies, pharmacokinetic profiling, and environmental fate studies such as degradation of chemicals in soil or water systems. Each of these studies is designed according to a predefined protocol before experimentation begins. Once the study starts, deviations from the protocol are tightly controlled, documented, and justified. This protocol-driven structure ensures that the study is not influenced by ad hoc experimental changes that could compromise data reliability. A defining feature of GLP is the concept of the study as the central unit of control. Unlike manufacturing systems where batches of products are the focus, GLP organizes all activity around individual studies. Each study has a Study Director who bears ultimate responsibility for scientific and regulatory compliance. The Study Director ensures that the study is conducted according to protocol, that data is accurately recorded, and that the final report reflects the true outcomes of the experiment. Supporting this structure is the Quality Assurance Unit (QAU), which operates independently from the study personnel. The independence of QA is critical because it ensures objective oversight. QA performs audits at different stages of the study, including protocol review, in-process monitoring, and final report verification.

One of the most important principles in GLP is raw data integrity. Every observation, measurement, and experimental result must be recorded at the time it is generated. This includes handwritten notes, instrument outputs, electronic data files, images, and any supplementary documentation. Importantly, GLP requires that raw data be preserved exactly as it was originally recorded, without unauthorized modification or selective reporting. This is essential because regulatory reviewers must be able to reconstruct the entire study from beginning to end without gaps or inconsistencies. The ability to reconstruct studies is what gives GLP its regulatory power. The documentation culture in GLP is extremely rigorous. It extends beyond final reports to include laboratory notebooks, instrument calibration records, standard operating procedures, and QA audit reports. Every aspect of the study must be traceable, including who performed a task, when it was performed, under what conditions it was performed, and what the outcome was. This traceability ensures accountability and eliminates ambiguity in data interpretation. Regulatory agencies often emphasize principles such as ALCOA (Attributable, Legible, Contemporaneous, Original, Accurate) to reinforce this level of data discipline.

Equipment used in GLP studies must be properly calibrated and maintained, but the emphasis is not on industrial-scale validation. Instead, validation focuses on ensuring that analytical methods used in studies are appropriate and reliable for measuring specific biological or chemical endpoints. The goal is reproducibility of scientific findings rather than consistency of production output. Because GLP studies are often exploratory in nature, equipment use is tied to experimental design rather than continuous manufacturing processes. Quality Assurance in GLP is structurally independent, which is one of its most distinctive features. The QAU does not participate in experimental work but instead audits study conduct and documentation. It verifies that the study follows the approved protocol, that deviations are documented appropriately, and that raw data supports the conclusions in the final report. This independence ensures that scientific interpretation is not influenced by those conducting the experiments. Regulatory inspections of GLP studies typically focus on whether this independence has been maintained and whether data integrity has been preserved throughout the study lifecycle.

From a regulatory perspective, GLP serves as the foundation for early-stage safety evaluation. It is used to determine whether a substance can safely proceed to clinical trials or environmental release. If GLP data is not reliable, regulatory authorities may reject entire studies, requiring them to be repeated at significant cost and delay. However, GLP non-compliance does not immediately affect public health because the studies occur before human exposure or product commercialization. GLP functions as a global standard for scientific credibility in non-clinical research. It ensures that safety data is not only scientifically valid but also transparently generated and fully traceable. Its role is to safeguard the integrity of knowledge rather than the integrity of manufactured products.

GOOD MANUFACTURING PRACTICE (GMP)

GMP is a regulatory system designed to ensure that products intended for human or animal use are consistently manufactured and controlled according to quality standards appropriate for their intended purpose. Unlike GLP, which focuses on preclinical data generation, GMP focuses on the entire lifecycle of product manufacturing, including production, packaging, testing, storage, and distribution. Its central objective is to ensure that every batch of a product is safe, effective, and consistent before it reaches the market. GMP operates in highly regulated industries such as pharmaceuticals, biologics, vaccines, and medical devices. Regulatory frameworks such as US FDA 21 CFR Parts 210 and 211, EU GMP guidelines, and WHO GMP standards define strict requirements for manufacturing systems. The fundamental philosophy of GMP is not scientific exploration but process control. It is designed to minimize variability in production and ensure that each unit of product meets predefined specifications.

In GMP systems, laboratory testing plays a critical but supportive role within Quality Control (QC) units. These laboratories do not conduct exploratory research but instead perform routine, standardized tests on raw materials, in-process samples, and finished products. The purpose of these tests is to verify compliance with specifications rather than to generate new scientific insights. Typical tests include potency assays, purity determination, dissolution testing, sterility testing, and microbial limits testing. These tests are essential for determining whether a batch can be released for distribution. A defining feature of GMP is its integration with manufacturing operations. Unlike GLP, where studies are discrete and independent, GMP operates as a continuous production system. Each batch of product is manufactured under tightly controlled conditions and must undergo testing and quality review before release. This creates a direct link between laboratory results and real-world product availability. If a test fails, the batch may be rejected, reprocessed, or investigated through formal deviation and corrective action systems.

The organizational structure of GMP is centered around production, quality control, and quality assurance functions. Production is responsible for manufacturing the product, QC is responsible for testing and verification, and QA oversees the entire system to ensure compliance with regulatory requirements. In some jurisdictions, particularly in the European Union, a Qualified Person (QP) holds legal responsibility for certifying that each batch meets all regulatory standards before it is released. This creates a direct accountability link between laboratory testing and market authorization. Documentation in GMP is centered on batch traceability. Every batch of product has a complete manufacturing record that includes raw material details, equipment identification, processing parameters, environmental conditions, operator signatures, and QC test results. These records ensure that every product can be traced back through its entire manufacturing history. Unlike GLP documentation, which reconstructs scientific experiments, GMP documentation reconstructs production events to ensure accountability and compliance.

Validation in GMP is significantly more comprehensive than in GLP because it covers not only analytical methods but also entire manufacturing systems. Equipment must undergo Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) to ensure that it functions correctly under production conditions. In addition, manufacturing processes themselves must be validated to demonstrate that they consistently produce products meeting predefined specifications. Cleaning validation, computerized system validation, and environmental monitoring are also required to prevent contamination and ensure product consistency. GMP laboratories operate under strict quality systems where testing is directly linked to batch release decisions. Once testing is complete, results are reviewed by QA and, where applicable, a Qualified Person before the product can be released to the market. This creates a direct regulatory impact from laboratory results to patient or consumer access. Failure in GMP compliance can therefore have immediate and serious consequences, including product recalls, regulatory sanctions, or shutdown of manufacturing facilities.

Regulatory inspections in GMP are comprehensive and system-wide. Inspectors evaluate not only laboratory practices but also manufacturing operations, documentation systems, personnel training, equipment validation, and deviation management systems. These inspections are designed to ensure that the entire production ecosystem consistently produces safe and compliant products. Unlike GLP inspections, which are study-specific, GMP inspections assess the entire facility’s operational integrity. At its core, GMP exists to ensure product reliability in real-world use. It transforms pharmaceutical and industrial manufacturing into a highly controlled system where variability is minimized and quality is built into every stage of production. While GLP ensures that scientific data used for decision-making is valid, GMP ensures that the products derived from those decisions are safe and consistent when they reach end users. GMP is a system of industrial discipline that ensures that what is produced is always consistent with what was intended. It safeguards public health by controlling manufacturing processes, enforcing rigorous testing, and maintaining strict accountability throughout the production lifecycle.

The distinction between Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) laboratory testing frameworks reflects two fundamentally different regulatory philosophies: one centered on the integrity of non-clinical scientific data generation, and the other on the assurance of consistent product quality within manufacturing systems (Table 1). Understanding these differences is essential for interpreting how regulatory compliance is operationalized across the drug development lifecycle, particularly in how responsibility, documentation, and quality oversight are structured in laboratory environments. Table 1 provides a structured comparison of these frameworks, highlighting how GLP is primarily focused on ensuring the integrity and traceability of non-clinical study data used in regulatory safety assessment, while GMP is centered on ensuring that manufactured products consistently meet predefined quality specifications before release. The comparison further clarifies how these differences are reflected in roles, quality systems, testing approaches, facility requirements, and record-keeping practices.

Table 1. GLP vs GMP Laboratory Testing Differences

Topic	Good Laboratory Practice (GLP)	Good Manufacturing Practice (GMP)
Study Director	Single appointed individual responsible for overall conduct, scientific integrity, and compliance of the study. Designated by Testing Facility Management.	No equivalent role. Responsibility is distributed across production, QC, and QA systems; no single study-level authority exists.
Quality Assurance / Quality Control	Independent Quality Assurance Unit (QAU) audits study phases, verifies compliance, and reports directly to management. Does not perform testing or control work.	Quality Control (QC) unit performs testing and has authority to accept or reject materials/products against specifications; QA oversees system compliance and release processes.
Testing Facility Management	Ensures qualified Study Director is assigned, maintains independent QAU, and provides adequate resources, equipment, and trained personnel for studies.	Ensures trained supervisors, validated systems, and compliance with SOPs; responsible for maintaining controlled manufacturing and quality systems.
Type of Testing Conducted	Non-clinical, open-ended experimental studies for regulatory safety assessment (e.g., toxicology, pharmacokinetics, environmental studies).	Routine, specification-driven testing of raw materials, in-process samples, and finished products to confirm compliance for release.
Facility Requirements	Facilities must support study integrity, minimize contamination/mix-ups, and ensure traceability; infrastructure requirements less prescriptive.	Highly regulated facility design with strict environmental controls, segregation of areas, controlled utilities (HVAC, water systems, cleaning zones). HVAC-Heating, Ventilation, and Air Conditioning systems
Equipment	Must be suitable for study purpose, calibrated, and fully documented to ensure study reconstructability; focus on experimental accuracy.	Must be qualified (IQ/OQ/PQ where applicable), validated for manufacturing use, and routinely calibrated to ensure consistent product quality. IQ-installation qualificationOQ-operational qualificationPQ-performance qualification
Standard Operating Procedures (SOPs)	Developed by qualified personnel and approved by management; may be adapted per study requirements.	Strictly controlled, formally approved by QA/QC; used consistently with minimal deviation across production activities.
Study Protocol / Process Control	Each study requires a detailed protocol defining objectives, methods, and analysis; deviations require documentation and justification.	No study protocols; manufacturing follows validated processes and batch records rather than experimental protocols.
Master Schedule / Indexing	QAU maintains a master schedule listing all ongoing and completed studies for audit tracking.	Not formally required as a regulatory element in GMP systems.
Records and Reports	Full raw data traceability required; all entries signed, dated, and attributable. Archiving required for long-term regulatory access (typically 2–5+ years depending on use).	Batch records require dual verification (operator + reviewer). Records retained typically until product expiry plus defined period; focus on batch traceability.
CAPA System	Not a mandatory structural requirement (may exist but not central to GLP framework).	Mandatory Corrective and Preventive Action (CAPA) system to investigate deviations, prevent recurrence, and maintain continuous quality improvement.

Source:

www.certara.com/2013/12/09/what-is-glp-good-laboratory-practice/?

www.ispe.org/initiatives/regulatory-resources/gmp/what-is-gmp

www.who.int/biologicals/vaccines/good_manufacturing_practice/en/

www.microchemlab.com/information/what-difference-between-glp-and-gmp-laboratory-testing-regulations